中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.014 seconds)

    SUBSTANCES
    1.
    发明申请
    SUBSTANCES 审中-公开
    物质

    公开(公告)号：WO2002102840A2

    公开(公告)日：2002-12-27

    申请号：PCT/GB2002/002866

    申请日：2002-06-19

    Applicant: AVIDEX LIMITED ,  JAKOBSEN, Bent, Karsten ,  BOULTER, Jonathan, Michael

    Inventor： JAKOBSEN, Bent, Karsten ,  BOULTER, Jonathan, Michael

    IPC: C07K14/00

    CPC classification number: C07K14/70539 ,  A61K48/00

    Abstract: The present invention provides a multimers of class I Major Histocompatibility Complexes (MHCs) having a modified P2-microglobulin whose binding to CD8 is inhibited. Such MHCs are capable of inhibiting CD8 + T cell response, particularly by inducing apoptosis or anergy of the T cell. The invention also provides nucleic acids encoding such molecules, and the use of such multimers and nucleic acids in immunosuppressive therapy, in particular as inhibitors of cytotoxic T cell responses.

    Abstract translation: 本发明提供具有与CD8结合被抑制的经修饰的P2-微球蛋白的I类主要组织相容性复合物（MHC）的多聚体。 这样的MHC能够抑制CD8 + T细胞反应，特别是通过诱导T细胞的凋亡或无反应性。 本发明还提供了编码这种分子的核酸，以及这些多聚体和核酸在免疫抑制治疗中的用途，特别是作为细胞毒性T细胞应答的抑制剂。

    CELLS TRANSFORMED WITH NUCLEIC ACID ENCODING NY-ESO T CELL RECEPTORS
    3.
    发明申请
    CELLS TRANSFORMED WITH NUCLEIC ACID ENCODING NY-ESO T CELL RECEPTORS 审中-公开
    用核酸编码NY-ESO T细胞受体的细胞转化

    公开(公告)号：WO2008037943A1

    公开(公告)日：2008-04-03

    申请号：PCT/GB2006/003649

    申请日：2006-09-29

    Applicant: MEDIGENE LIMITED ,  JAKOBSEN, Bent, Karsten ,  BOULTER, Jonathan, Michael ,  LI, Yi ,  MOLLOY, Peter, Eamon ,  DUNN, Steven, Mark

    Inventor： JAKOBSEN, Bent, Karsten ,  BOULTER, Jonathan, Michael ,  LI, Yi ,  MOLLOY, Peter, Eamon ,  DUNN, Steven, Mark

    IPC: C07K14/705

    CPC classification number: C07K14/70503

    Abstract: The present invention provides cells transformed with expressible nucleic acids encoding a TCR specific for the SLLMWITQC-HLA-A*0201 complex, said nucleic acids consisting of: (i) a sequence comprising bases 15 to 836 of SEQ ID Nos: 1, 3, 5, 7, or 9, and (ii) a sequence comprising bases 16 to 948 of SEQ ID Nos: 11, 13, 15, 17, 19, or 21 or; (a) a sequence comprising bases 15 to 836 of SEQ ID Nos: 23, 25, 27, 29 or 31 and (b) a sequence comprising bases 16 to 948 of SEQ ID Nos: 33, 35, 37, 39, 41, or 43. Such cells are useful for targeting NY-ESO + cancer cells presenting the SLLMWITQC-HLA-A*0201 complex.

    Abstract translation: 本发明提供用编码针对SLLMWITQC-HLA-A * 0201复合物的TCR特异性的可表达核酸转化的细胞，所述核酸由以下组成：（i）包含SEQ ID No：1,3， 5，7或9，和（ii）包含SEQ ID NO：11,13,15,17,19或21的碱基16至948的序列; （a）包含SEQ ID No：23,25,27,29或31的碱基15至836的序列和（b）包含SEQ ID No：33,35,37,39,41， 这种细胞可用于靶向呈现SLLMWITQC-HLA-A * 0201复合物的NY-ESO +癌细胞。

    GAMMA-DELTA T CELL RECEPTORS
    4.
    发明申请
    GAMMA-DELTA T CELL RECEPTORS 审中-公开
    GAMMA-DELTA T细胞受体

    公开(公告)号：WO2006056733A1

    公开(公告)日：2006-06-01

    申请号：PCT/GB2005/004198

    申请日：2005-10-31

    Applicant: AVIDEX LTD ,  BOULTER, Jonathan, Michael

    Inventor： BOULTER, Jonathan, Michael

    IPC: C12N15/12 ,  G01N33/68 ,  C12N15/62 ,  A61K38/17

    CPC classification number: C07K14/7051 ,  G01N33/56972

    Abstract: The present invention provides gamma-delta T cell receptors (γδTCRs) with an introduced disulfide interchain bond. Such proteins, and cells expressing of such proteins on the surface thereof, have value in methods for distinguishing between cell populations by the TCR ligand they present, and in the treatment of diseases.

    Abstract translation: 本发明提供具有引入的二硫键间连接键的γ-δT细胞受体（βdTCR）。 这样的蛋白质和在其表面上表达这种蛋白质的细胞在通过其存在的TCR配体和疾病的治疗来区分细胞群体的方法中具有价值。

    METHOD OF IMPROVING T CELL RECEPTORS
    8.
    发明申请
    METHOD OF IMPROVING T CELL RECEPTORS 审中-公开
    改进T细胞受体的方法

    公开(公告)号：WO2005114215A9

    公开(公告)日：2006-07-20

    申请号：PCT/GB2005001781

    申请日：2005-05-10

    Applicant: AVIDEX LTD ,  DUNN STEVEN MARK ,  LI YI ,  BOULTER JONATHAN MICHAEL

    Inventor： DUNN STEVEN MARK ,  LI YI ,  BOULTER JONATHAN MICHAEL

    IPC: C12N15/10 ,  C07K14/725 ,  C40B40/02 ,  G01N33/68

    CPC classification number: C40B40/02 ,  C07K14/7051 ,  C12N15/1037

    Abstract: A method of increasing the affinity and/or decreasing the off-rate of a given TCR specific for a given target pMHC, comprising creating a plurality of TCRs having an a chain CDR2 sequence and/or a ß chain CDR2 sequence different from the corresponding CDR2 sequence(s) of the given TCR but having the same a and ß CDR1 and CDR3 sequences as the given TCR, determining the affinity and/or off-rate of members of said plurality of TCRs for the target pMHC, and selecting one or more members having at least a 10-fold greater affinity for the target pMHC than the given TCR and/or a 10-fold slower off-rate for the target pMHC than the given TCR.

    Abstract translation: 提高对给定靶pMHC具有特异性的给定TCR的亲和力和/或降低解离速率的方法，包括产生多个具有不同于相应CDR2的链CDR2序列和/或β链CDR2序列的TCR 给定TCR的序列，但具有与给定TCR相同的α和βCDR1和CDR3序列，确定所述多种TCR成员对靶pMHC的亲和力和/或解离速率，并选择一种或多种 成员对靶标pMHC具有比给定TCR至少10倍以上的亲和力和/或对于靶标pMHC具有比给定TCR更慢10倍的解离速率。

    METHOD OF IMPROVING T CELL RECEPTORS
    9.
    发明申请
    METHOD OF IMPROVING T CELL RECEPTORS 审中-公开

    公开(公告)号：WO2005114215A3

    公开(公告)日：2005-12-01

    申请号：PCT/GB2005/001781

    申请日：2005-05-10

    Applicant: AVIDEX LTD ,  DUNN, Steven, Mark ,  LI, Yi ,  BOULTER, Jonathan, Michael

    Inventor： DUNN, Steven, Mark ,  LI, Yi ,  BOULTER, Jonathan, Michael

    IPC: C12N15/10

    Abstract: A method of increasing the affinity and/or decreasing the off-rate of a given TCR specific for a given target pMHC, comprising creating a plurality of TCRs having an α chain CDR2 sequence and/or a β chain CDR2 sequence different from the corresponding CDR2 sequence(s) of the given TCR but having the same α and β CDR1 and CDR3 sequences as the given TCR, determining the affinity and/or off-rate of members of said plurality of TCRs for the target pMHC, and selecting one or more members having at least a 10-fold greater affinity for the target pMHC than the given TCR and/or a 10-fold slower off-rate for the target pMHC than the given TCR.

Patent Agency Ranking